A recent study has found that a new single-pill combination of telmisartan, amlodipine, and indapamide, known as GMRx2, provides superior blood pressure control compared to traditional dual therapies for managing hypertension. The findings were presented by Dr. Alexander R. van Rosendael at the TCT 2024 conference.
The study revealed that patients using GMRx2 experienced a greater reduction in home systolic blood pressure (SBP) over 12 weeks compared to those on dual combination therapies. Additionally, clinic blood pressure control was significantly better with GMRx2.
Study Overview
The research evaluated the effectiveness and safety of GMRx2 against dual therapy options. It included a diverse group of hypertensive patients from seven countries. The primary goal was to measure the change in home SBP from baseline to 12 weeks. The study also looked at clinic blood pressure rates as a secondary outcome.
Between July 9, 2021, and September 1, 2023, a total of 3,109 patients were screened for eligibility. Ultimately, 1,385 patients were included in the final analysis: 551 received GMRx2, while others were assigned to various dual combinations of the same drugs.
Results showed that patients taking GMRx2 achieved a mean SBP of 126 mmHg at 12 weeks. This was significantly lower than those on dual therapies, which had mean SBP reductions ranging from -2.5 mmHg to -5.4 mmHg.
In terms of clinic blood pressure control, 74% of patients on GMRx2 reached levels below 140/90 mmHg, compared to only 53-61% in the dual combination groups.
Key Findings
Dr. van Rosendael noted that the study confirmed the effectiveness of analyzing both lumen diameter and plaque volume for predicting patient risk. He emphasized that using AI can simplify this analysis for healthcare providers.
James K. Min, CEO of Cleerly, highlighted the importance of these findings in improving hypertension management. He stated that GMRx2’s ability to provide accurate measurements and enhance early intervention could significantly reduce serious cardiovascular events.
Conclusion
The study suggests that GMRx2 is an effective and well-tolerated option for improving blood pressure control in patients with hypertension. With its promising results, this novel triple therapy could play a crucial role in addressing the global challenge of hypertension management.
Related topics:
